Assessing a Novel Thyroid-Stimulating Antibody Bioassay as a Predictor of Radioactive Iodine Therapy Efficacy in Graves' Disease
TSAb (Bio) is a useful predictor of RAIT efficacy when evaluated as I-131 absorbed dose/(TSAb (Bio)/TRAb). This index was defined by dividing a factor that positively affects RAIT outcomes (I-131 absorbed dose) by a factor negatively affecting it (i.e., (TSAb (Bio)/TRAb)). The therapeutic efficacy of RAIT can be expected with an I-131 absorbed dose/(TSAb (Bio)/TRAb) value of ≥3.9. Adjusting the I-131 dosage based on this index may lead to more effective treatment outcomes.
Authors
- Yuji Nagayama (ORCID: https://orcid.org/0000-0002-5058-9349)
- Hisakazu Shindo (ORCID: https://orcid.org/0000-0002-1424-620X)
- Hiroyuki Yamashita
- Daisuke Tatsushima (ORCID: https://orcid.org/0000-0001-9802-3697)
- Seigo Tachibana (ORCID: https://orcid.org/0000-0003-4154-500X)
- Hiroshi Takahashi (ORCID: https://orcid.org/0000-0001-5957-8286)
- Takashi Fukuda (ORCID: https://orcid.org/0000-0003-1635-4471)
- Shinya Sato (ORCID: https://orcid.org/0000-0003-3049-3443)
- Yusuke Mori (ORCID: https://orcid.org/0009-0003-4297-134X)
- Kento Katsuyama (ORCID: https://orcid.org/0009-0001-2844-1823)
Institutions
- Noguchi Thyroid Clinic and Hospital Foundation (JP)
- Fukuoka Hospital (JP)
- Yamashita Thyroid Hospital
Publication Details
- Journal
- Cureus
- Published
- 2024-12-31
- DOI
- https://doi.org/10.7759/cureus.76698
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00